文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

佐利氟达星(ETX0914)对耐大环内酯类、耐氟喹诺酮类及抗菌药物敏感的生殖支原体菌株的体外活性

In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该研究采用Vero细胞培养和定量PCR法,检测佐利氟达星对47株生殖支原体的体外活性,其中包括34株莫西沙星敏感株和13株莫西沙星耐药株,23株阿奇霉素耐药株,12株MDR株。结果显示仅1株(2.1%)出现MIC显著升高(4 mg/L)且可能对佐利氟达星耐药,佐利氟达星总体活性强于莫西沙星(P=0.009),两类拓扑异构酶II抑制剂间未见交叉耐药。

要点

  • 47株生殖支原体中仅1株(2.1%)对佐利氟达星MIC升高至4 mg/L,可能耐药。
  • 佐利氟达星总体活性强于莫西沙星(P=0.009),两类药物间未见交叉耐药。
  • 23株(48.9%)对阿奇霉素耐药,而仅1株(2.1%)可能对佐利氟达星耐药。

核心结论

  • 佐利氟达星是治疗生殖支原体的有前景候选药物,有必要进一步开发和评估该药物。

研究设计与样本

  • 通过Vero细胞培养生殖支原体并用定量PCR测定生长,评估佐利氟达星对47株生殖支原体菌株的体外活性。
  • 菌株集合包括34株莫西沙星敏感株(MIC <1 mg/L)和13株莫西沙星耐药株(MIC ≥1 mg/L)。
  • 其中23株为阿奇霉素耐药株(MIC ≥16 mg/L),12株为MDR株。

主要发现

  • 仅1株(2.1%)出现MIC显著升高(4 mg/L)且可能对佐利氟达星耐药。
  • 佐利氟达星总体活性强于莫西沙星(P = 0.009),两类拓扑异构酶II抑制剂间未观察到交叉耐药。
  • 佐利氟达星与阿奇霉素的MIC差异无统计学显著;23株(48.9%)对阿奇霉素耐药,而可能对佐利氟达星耐药的菌株为1株(2.1%)。

关键数值与推荐

  • 莫西沙星敏感定义为MIC <1 mg/L,耐药定义为MIC ≥1 mg/L。
  • 阿奇霉素耐药定义为MIC ≥16 mg/L。
  • 佐利氟达星可能耐药对应MIC为4 mg/L。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycoplasma genitalium is estimated to be the second most common cause of bacterial sexually transmitted infection in Europe. It is of increasing public health concern due to the rapid development of resistance to different antimicrobial classes, including the preferred first- and second-line treatments azithromycin and moxifloxacin. Thus, new antimicrobial agents are urgently needed, especially for the treatment of MDR strains. METHODS: The in vitro activity of the new spiropyrimidinetrione zoliflodacin against 47 M. genitalium strains was assessed by growing M. genitalium in Vero cell culture and measuring growth by quantitative PCR. The collection included 34 moxifloxacin-susceptible (MIC <1 mg/L) and 13 moxifloxacin-resistant (MIC ≥1 mg/L) strains. Twenty-three of the strains were azithromycin resistant (MIC ≥16 mg/L) and 12 of these strains were MDR. RESULTS: Only one (2.1%) strain with substantially increased MIC (4 mg/L) and potential resistance to zoliflodacin was found. Zoliflodacin was overall more potent than moxifloxacin (P = 0.009) and no cross-resistance was observed between the two drug classes of topoisomerase II inhibitors. Differences in the MICs of zoliflodacin and azithromycin were not statistically significant; however, 23 (48.9%) compared with potentially 1 (2.1%) of the strains were resistant to azithromycin and zoliflodacin, respectively. CONCLUSIONS: Zoliflodacin is a promising candidate for the treatment of M. genitalium and it is important to further develop and evaluate this drug.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Damião Gouveia AC, Unemo M, Jensen JS, et al. In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains. J Antimicrob Chemother. 2018. PMID: 29444242. doi:10.1093/jac/dky022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。